Get the Stockscreener App
1.17
12.50%
0.13
After Hours:
1.15
-0.02
-1.71%
NanoViricides Inc stock is traded at $1.17, with a volume of 256.31K.
It is up +12.50% in the last 24 hours and down -0.85% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.04
Open:
$1.05
24h Volume:
256.31K
Relative Volume:
1.03
Market Cap:
$25.27M
Revenue:
-
Net Income/Loss:
$-8.32M
P/E Ratio:
-2.4294
EPS:
-0.4816
Net Cash Flow:
$-7.43M
1W Performance:
+6.36%
1M Performance:
-0.85%
6M Performance:
-18.75%
1Y Performance:
-12.03%
1-Day Range:
$1.05
$1.18
1-Week Range:
$0.9827
$1.18
52-Week Range:
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.17 | 22.46M | 0 | -8.32M | -7.43M | -0.4816 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | Alliance Global Partners | Buy |
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides - ACCESS Newswire
NanoViricides to Present at the 15th Annual BIO-CEO Conference in NYC Tomorrow - AOL.com
Profit Recap: Can NanoViricides Inc continue delivering strong returns2026 Volatility Report & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
NanoViricides seeks FDA’s rare pediatric disease designation for antiviral candidate NV-387ICYMI - Proactive financial news
Macro Review: Should I hold or sell GMREPRA now2026 Spike Watch & Community Consensus Stock Picks - baoquankhu1.vn
Weekly Earnings: Is NanoViricides Inc subject to activist investor interestTake Profit & Real-Time Buy Signal Notifications - baoquankhu1.vn
NNVC Forecast, Price Target & Analyst Ratings | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
Aug Summary: Is NanoViricides Inc undervalued by DCF analysisWeekly Gains Report & Stock Timing and Entry Methods - baoquankhu1.vn
NanoViricides files for Rare Pediatric Disease Designation for Measles Drug - Proactive financial news
Growth Value: Can NanoViricides Inc stock double in the next year2026 Technical Overview & Short-Term Trading Alerts - baoquankhu1.vn
NNVC Ownership | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
Activity Recap: Is NanoViricides Inc forming a bullish divergencePortfolio Value Report & Short-Term Swing Trade Alerts - baoquankhu1.vn
NanoViricides Seeks Rare Pediatric Disease Designation for Measles Treatment Candidate - citybuzz -
Measles Rare Pediatric Disease Drug Designation Application File - GuruFocus
NanoViricides seeks rare pediatric disease status for measles drug NV-387 - Yahoo Finance
About Us - FinancialContent
Aug Shorts: Is NanoViricides Inc forming a breakout pattern2026 Earnings Impact & Short-Term Swing Trade Alerts - baoquankhu1.vn
Small caps wrap: Alvopetro Energy, NanoViricides, New Era Energy & Digital, Digi Power X… - proactiveinvestors.co.uk
NanoViricides to Begin Phase II MPox Clinical Trial in Democratic Republic of Congo - citybuzz -
Small cap wrap: Alvopetro Energy, NanoViricides, New Era Energy & Digital, Digi Power X… - Proactive financial news
NanoViricides to begin Phase II trial of MPox treatment in Congo - Proactive financial news
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides - ACCESS Newswire
Monkeypox drug trial cleared in Congo as NanoViricides readies dosing - Stock Titan
Tangible book value per share of NanoViricides, Inc. – MUN:NV3P - TradingView
Forecast Cut: Is NanoViricides Inc subject to activist investor interest2026 Patterns & Smart Money Movement Tracker - baoquankhu1.vn
Reviewing NanoViricides (NYSE:NNVC) & Spruce Biosciences (NASDAQ:SPRB) - Defense World
NNVC Should I Buy - Intellectia AI
Growth Recap: Should I hold or sell NanoViricides Inc nowTrade Ideas & Risk Controlled Daily Plans - baoquankhu1.vn
NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete - ACCESS Newswire
NNVC Stock Price, Quote & Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
Aug Retail: Can NanoViricides Inc generate free cash flowEarnings Beat & Real-Time Volume Analysis - baoquankhu1.vn
NanoViricides (NYSE:NNVC) Stock Price Down 4.8% – What’s Next? - Defense World
If You Invested $1,000 in Nanoviricides (NNVC) - Stock Titan
EBITDA per share of NanoViricides, Inc. – FWB:NV3P - TradingView
Volume Recap: Can NanoViricides Inc grow without external funding2026 Momentum Check & Consistent Return Strategy Ideas - baoquankhu1.vn
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Beaver County Times
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides - The Register-Guard
NanoViricides, Inc. Has Filed its Quarterly ReportSubsequent Raise Has Fortified Fiscal Position - The Asheville Citizen Times
NanoViricides Completes Manufacturing of NV-387 Oral Gummies, Prepares for Phase II Monkeypox Trial - citybuzz -
Aug Setups: Can NanoViricides Inc continue delivering strong returns2026 EndofMonth & Stepwise Trade Execution Plans - baoquankhu1.vn
Small cap wrap: NanoViricides, Millennial Potash, Gunnison Copper, Century Lithium… - Proactive Investors
NanoViricides completes manufacturing of NV-387 oral drug ahead of Phase II mpox trial - Yahoo! Finance Canada
Antiviral NV-387 heads to Phase II mpox trial with new gummy form - Stock Titan
Jobs Data: Can NanoViricides Inc continue delivering strong returnsMarket Volume Report & Community Verified Trade Signals - baoquankhu1.vn
Sell Signal: Is NanoViricides Inc subject to activist investor interest2025 Investor Takeaways & Low Risk Growth Stock Ideas - baoquankhu1.vn
NNVC Earnings History & Surprises | EPS & Revenue Results | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 - The Asheville Citizen Times
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):